FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2586240666> ?p ?o ?g. }

• W2586240666 abstract "Abstract CLO is a nucleoside analog with ribonucleotide reductase inhibitory activity. As such, CLO has the ability to impede repair of damaged DNA. We designed a Phase I clinical trial of CLO followed by CY for adults with refractory acute leukemias, with escalating doses of CLO (beginning10 mg/m2/day) and CY (beginning 400 mg/m2/day) days 1–3 and 8–10. The first CY dose was split between Day 0 and Day 1 at 200 mg/m2/dose to test the hypothesis that CLO could increase CY-induced DNA damage in leukemic blasts. Peripheral blood blasts were obtained prior to CY (Pre), at end Day 0 CY 2 hr infusion (Day 0 EOI), 2 hrs after Day 0 CY EOI (Day 0 Post), and Day 1 2 hrs after CLO-CY EOI (Day 1 Post). DNA damage was measured serially by flow cytometry of cells stained with antibody to phosphorylated histone H2AX (γH2AX). Apoptosis was measured at each time point by propidium iodide (PI) staining as sub2N DNA. To date, we have studied peripheral blood blasts from 9 patients at 2 CLO doses (10 and 20 mg/m2/day) and CY total daily dose 400 mg/m2. γH2AX was detected in a median 1.32% of Pre cells (range 0–6.1). Relative to Pre, there was median 2-fold increase in γH2AX (range 0.3–6) in Day 0 EOI cells with less damage detected in Day 0 Post cells (median 1.1, range 0–3.3). Day 1 Post cells evinced median 6.3-fold increase in γH2AX staining (range 1.5–38) relative to Pre, with 6/9 patients have a >2-fold increase, and median 9.2-fold increase (range 0.9–38) relative to Day 0 Post with >2-fold increase in 7/9 patients. Relative to Pre cells, there was no increase in the fraction of cells exhibiting sub2N DNA (median 0.9, range 0.34–22, >1.2-fold increase in 4/9) in Day 0 Post samples. In contrast, Day 1 Post samples had median 1.4-fold (range 0.3–61) increase in cells with sub2N DNA, with 7/9 patients having >1.2 fold increases. In this small number of patients, there was no clear relationship between CLO dose and magnitude of DNA damage or apoptosis induced in Day 1 Post cells. In 5 patients with complete tumor clearance in Day 14 marrow, there was median 11-fold increase (range 0.3–62) in γH2AX staining in Day 1 Post cells relative to Pre cells and median 5.7-fold increase (range 0.9–33) over Day 0 Post cells. In 3 patients who had residual leukemia present on Day 14, the median increase in γH2AX over Pre was 1.7-fold (1.5,1.7,38). WBC nadir was 0 (range 0–50) occurred on median day 12 (range 10–20). WBC recovery to >500/mm3 occurred in 7 patients on median day 32 (range 27–75), 1 patient with refractory AML died Day 14 of multi-organ failure, and 1 patient with refractory ALL post autologous transplant died on day 100 in marrow aplasia. Two patients with refractory AML achieved responses: 1 CR, 1 PR. Interestingly, the patient who achieved CR had the highest Pre γH2AX and Day 1 Post levels (38.6%). In summary, our in vivo correlative data suggest that DNA damage that occurs following CY, as measured by γH2AX, is augmented by prior CLO administration and correlates with tumor clearance by Day 14. With accrual and study of additional patients, we should be able to determine any relationship between magnitude of increase in DNA damage and clinical outcomes." @default.
• W2586240666 created "2017-02-17" @default.
• W2586240666 creator A5013544426 @default.
• W2586240666 creator A5036251329 @default.
• W2586240666 creator A5040758762 @default.
• W2586240666 creator A5079274832 @default.
• W2586240666 creator A5089694123 @default.
• W2586240666 date "2006-11-16" @default.
• W2586240666 modified "2023-10-02" @default.
• W2586240666 title "Phase I Clinical-Laboratory Trial of Clofarabine (CLO) Followed by Cyclophosphamide (CY) for Adults with Refractory Acute Leukemias: Evidence for Enhanced DNA Damage." @default.
• W2586240666 doi "https://doi.org/10.1182/blood.v108.11.1963.1963" @default.
• W2586240666 hasPublicationYear "2006" @default.
• W2586240666 type Work @default.
• W2586240666 sameAs 2586240666 @default.
• W2586240666 citedByCount "0" @default.
• W2586240666 crossrefType "journal-article" @default.
• W2586240666 hasAuthorship W2586240666A5013544426 @default.
• W2586240666 hasAuthorship W2586240666A5036251329 @default.
• W2586240666 hasAuthorship W2586240666A5040758762 @default.
• W2586240666 hasAuthorship W2586240666A5079274832 @default.
• W2586240666 hasAuthorship W2586240666A5089694123 @default.
• W2586240666 hasConcept C126322002 @default.
• W2586240666 hasConcept C143425029 @default.
• W2586240666 hasConcept C153911025 @default.
• W2586240666 hasConcept C16685009 @default.
• W2586240666 hasConcept C185592680 @default.
• W2586240666 hasConcept C190283241 @default.
• W2586240666 hasConcept C203014093 @default.
• W2586240666 hasConcept C2775934118 @default.
• W2586240666 hasConcept C2776694085 @default.
• W2586240666 hasConcept C2776755627 @default.
• W2586240666 hasConcept C2777198975 @default.
• W2586240666 hasConcept C2778041864 @default.
• W2586240666 hasConcept C2778461978 @default.
• W2586240666 hasConcept C31573885 @default.
• W2586240666 hasConcept C552990157 @default.
• W2586240666 hasConcept C55493867 @default.
• W2586240666 hasConcept C71924100 @default.
• W2586240666 hasConcept C86803240 @default.
• W2586240666 hasConceptScore W2586240666C126322002 @default.
• W2586240666 hasConceptScore W2586240666C143425029 @default.
• W2586240666 hasConceptScore W2586240666C153911025 @default.
• W2586240666 hasConceptScore W2586240666C16685009 @default.
• W2586240666 hasConceptScore W2586240666C185592680 @default.
• W2586240666 hasConceptScore W2586240666C190283241 @default.
• W2586240666 hasConceptScore W2586240666C203014093 @default.
• W2586240666 hasConceptScore W2586240666C2775934118 @default.
• W2586240666 hasConceptScore W2586240666C2776694085 @default.
• W2586240666 hasConceptScore W2586240666C2776755627 @default.
• W2586240666 hasConceptScore W2586240666C2777198975 @default.
• W2586240666 hasConceptScore W2586240666C2778041864 @default.
• W2586240666 hasConceptScore W2586240666C2778461978 @default.
• W2586240666 hasConceptScore W2586240666C31573885 @default.
• W2586240666 hasConceptScore W2586240666C552990157 @default.
• W2586240666 hasConceptScore W2586240666C55493867 @default.
• W2586240666 hasConceptScore W2586240666C71924100 @default.
• W2586240666 hasConceptScore W2586240666C86803240 @default.
• W2586240666 hasLocation W25862406661 @default.
• W2586240666 hasOpenAccess W2586240666 @default.
• W2586240666 hasPrimaryLocation W25862406661 @default.
• W2586240666 hasRelatedWork W1607099106 @default.
• W2586240666 hasRelatedWork W1944227239 @default.
• W2586240666 hasRelatedWork W2053903261 @default.
• W2586240666 hasRelatedWork W2060421679 @default.
• W2586240666 hasRelatedWork W2228697322 @default.
• W2586240666 hasRelatedWork W2488091784 @default.
• W2586240666 hasRelatedWork W2586240666 @default.
• W2586240666 hasRelatedWork W2748952813 @default.
• W2586240666 hasRelatedWork W2899084033 @default.
• W2586240666 hasRelatedWork W2467255834 @default.
• W2586240666 isParatext "false" @default.
• W2586240666 isRetracted "false" @default.
• W2586240666 magId "2586240666" @default.
• W2586240666 workType "article" @default.